Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R
Department of general, digestive and endocrine surgery, Robert-Debré hospital, CHU de Reims, Reims Champagne-Ardenne university, 8, rue du général Koenig, 51100 Reims, France.
Department of gastroenterology, Beaujon hospital, University Paris 7, AP-HP, 100, boulevard du Général-Leclerc, 92110 Clichy, France.
J Visc Surg. 2018 Apr;155(2):117-125. doi: 10.1016/j.jviscsurg.2017.12.008. Epub 2018 Feb 12.
The management of patients with pancreatic neuroendocrine tumor (PNET), whether hormonally secretory or not, is multidisciplinary and often multimodal. Surgical treatment plays a central role because complete resection is the only potentially curative treatment. The choice of the therapeutic plan for a PNET requires precise localization of the primary tumor (which may sometimes be multiple in case of genetic predisposition), confirmation of the diagnosis of PNET, a search for metastases (mainly hepatic), and identification of the main histoprognostic factors. This update focuses on the WHO 2017 histological classification and recent innovations in the preoperative assessment of PNET using conventional and isotopic imaging. The aim is to not only allow the mapping of primary and metastatic lesions but also to predict tumor aggressiveness.
胰腺神经内分泌肿瘤(PNET)患者的管理,无论其是否具有激素分泌功能,都需要多学科且通常是多模式的治疗。手术治疗起着核心作用,因为完整切除是唯一可能治愈的治疗方法。PNET治疗方案的选择需要对原发性肿瘤进行精确定位(在存在遗传易感性的情况下,原发性肿瘤有时可能是多发的)、确认PNET的诊断、寻找转移灶(主要是肝转移)以及识别主要的组织预后因素。本综述聚焦于世界卫生组织2017年组织学分类以及使用传统和同位素成像对PNET进行术前评估的最新创新技术。目的不仅是要对原发性和转移性病变进行定位,还要预测肿瘤的侵袭性。